Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) now have 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $1,184.00 and $710.00 calculating the mean target share price we have $1,023.41. (at the time of writing). Given that the stocks previous close was at $993.35 this indicates there is a potential upside of 3.0%. The day 50 moving average is $925.48 and the 200 day MA is $822.75. The market cap for the company is 108.40B. The stock price is currently at: $987.61 USD
The potential market cap would be $111,682,429,145 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 28.4, revenue per share of $122.94 and a 8.49% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
